Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 995 | 1068 | 1022 | 1149 | 1254 | 1761 |
Fund Return | -0.53% | 6.81% | 2.21% | 4.73% | 4.64% | 5.82% |
Place in category | 182 | 65 | 121 | 135 | 109 | 34 |
% in Category | 43 | 15 | 30 | 33 | 33 | 14 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
FC Responsible Global Equity Fund 2 | 1.28B | 9.14 | 6.49 | 12.49 | ||
FC Responsible Global Equity 2 Acc | 1.28B | 5.81 | 6.53 | 12.17 | ||
FC Responsible Global Equity 4 Inc | 1.28B | 5.95 | 7.30 | 12.94 | ||
FC Responsible Global Equity 1 Acc | 1.28B | 5.68 | 5.70 | 11.23 | ||
FC Responsible Global Equity 1 Inc | 1.28B | 5.64 | 5.43 | 11.09 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Liontrust Special Situations Fund R | 39.45M | -1.48 | 2.55 | 6.09 | ||
Liontrust Special Situations Fund A | 5.98M | 0.92 | 2.88 | 7.38 | ||
Liontrust Special Situations Fund I | 2.77B | 0.98 | 3.14 | 7.62 | ||
Fidelity Special Situations Fund W | 2.33B | 4.72 | 7.67 | 6.67 | ||
Fidelity Special Situations | 423.58M | -1.00 | 7.74 | 4.82 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
AstraZeneca | GB0009895292 | 6.54 | 12,050.0 | -0.87% | |
Unilever | GB00B10RZP78 | 4.20 | 48.80 | -0.02% | |
Experian | GB00B19NLV48 | 3.16 | 3,277.0 | +0.65% | |
Ashtead Group | GB0000536739 | 3.01 | 5,704.0 | +1.21% | |
GSK plc | GB00BN7SWP63 | 2.96 | 1,733.50 | +0.29% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review